1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 14 MARCH 2016

Cancer Drug News 14 MARCH 2016

  • March 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Towards Harmonising Transatlantic Review Times
Industry Trend Analysis - Zydelig Woes Underscore Need For Scale-Up In Diversification Efforts
Industry Brief - FDA Grants ODD To ProNAi's PNT2258 For DLBCL
Industry Brief - Variation To Arzerra Marketing Authorisation Filed With EMA
Industry Brief - DSMB Recommends Advancing Medigene's DC AML Vaccine To Phase II
Industry Brief - Pfizer's Xalkori Granted FDA Approval For ROS1-Positive Metastatic NSCLC
Industry Brief - Imbruvica FDA-Approved For First-line Treatment Of CLL
Industry Brief - FDA Accepts Keytruda sBLA In Advanced NSCLC
Industry Brief - FDA ODD For Soricimed's SOR-C13 To Treat Ovarian Cancer
Industry Brief - XBiotech Submits Xilonix MAA In EU To Treat Advance CRC
Industry Brief - DSMB Recommends Discontinuation Of Celldex' Rintega Phase III Study In Glioblastoma
Industry Brief - Lenvima Launched In Israel To Treat Advanced Thyroid Cancer
Industry Trend Analysis - USD999 Whole Genome Sequencing Will Challenge Single Biomarker Tests
Industry Trend Analysis - Growing Cancer Burden Will Boost Revenue Earning Opportunities
Industry Brief - Aprea Completes Fundraising To Advance APR-246 Clinical Development
Industry Brief - Aspyrian Secures Series B Funding

Table Of Contents

Cancer Drug News 14 MARCH 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.